Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 38
- Registration Number
- NCT03121014
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
- Conditions
- Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeLangerhans Cell HistiocytosisAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaNon-Hodgkin LymphomaRecurrent Hodgkin LymphomaTherapy-Related Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT03096782
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Umbilical Cord Blood Transplantation From Unrelated Donors
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT03016806
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2021-09-16
- Target Recruit Count
- 32
- Registration Number
- NCT03018223
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 10
- Registration Number
- NCT02999984
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT02916979
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- Conditions
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent High Risk Myelodysplastic SyndromeRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaHematopoietic and Lymphoid Cell NeoplasmRecurrent Acute Lymphoblastic LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Plasma Cell MyelomaHigh Risk Acute Myeloid LeukemiaLymphoproliferative Disorder
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT02861417
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Keimyung University Dongsan Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT02859402
- Locations
- 🇰🇷
Dong-A University, Busan, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02836639
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.